Dialysis independence for a young patient with refractory multiple myeloma treated with teclistamab: A case report

Teclistamab, a B‑cell maturation antigen‑targeting bispecific antibody, offers a promising treatment option for relapsed/refractory multiple myeloma (RRMM), even in patients with severe renal impairment. The present study describes the case of a 47‑year‑old woman with RRMM who achieved minimal residual disease negativity and dialysis independence following teclistamab treatment. Despite prior resistance to multiple therapies, including an anti‑CD38 monoclonal antibody (daratumumab), two proteasome inhibitors (bortezomib and carfilzomib), an immunomodulatory drug (lenalidomide), an exportin 1 inhibitor (selinexor), a BCL‑2 inhibitor (venetoclax) and dexamethasone, and post‑autologous stem cell transplantation relapse, teclistamab induced a deep hematological response. Cytokine release syndrome was manageable and no major complications occurred. The present case highlights the feasibility and effectiveness of teclistamab in patients with end‑stage renal disease.